Dementia of Alzheimer Type
Neurology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Araceli BiosciencesOR - Tigard
1 programMultifactorial Approach to Dementia, Multicentric StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IGC PharmaIGC AD1
Araceli BiosciencesMultifactorial Approach to Dementia, Multicentric Study
Clinical Trials (2)
Total enrollment: 450 patients across 2 trials
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Start: Jan 2021Est. completion: Jun 2021
Phase 1Completed
Multifactorial Approach to Dementia, Multicentric Study
Start: May 2023Est. completion: Sep 2024450 patients
N/AUnknown
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
9h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
9h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
9h ago
Director of Finance
CoMind
London, UK
9h ago
Electronics Engineering Manager
CoMind
London, UK
9h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space